내가 좋아할 만한 콘텐츠
Nothing else, that has the pot' to enhance the durability of topo1 adc's. Competition y's behind. If it works, it's a 'skip ahead of the line' ticket for every topo1 adc that is playing the 'safety card' for a overcrowded target. I have been told there are a few out there.. $idya
$IDYA LIFESCI PT $62 IDYA continues to highlight preclinical IDE034 monotherapy activity and enhanced durability in combination with PARGi in in vivo models: IDYA plans to submit additional preclinical data for PARG combinations (i.e., with IDE161) for a 1H 2026 medical…
Why is it that, even though @bioinvestor24 blocked me, I still get to watch him posting clueless things? Asking for a friend..
649 $idya jan45c traded on wednesday Maybe only 100Kish bet, but still noteworthy as breakeven is 30% higer. I surely wouldn't take on that risk unless i expected mid 50's.
$idya Fair value, 45+ FYI
If merck wants to dial ‘mtap’, I have a good idea who they should give a call
Kelun, Merck tout ADC as potential first-line treatment in lung cancer biopharmadive.com/news/kelun-mer… $MRK by @Lilah_Alvarado
🇨🇳 Huaota announced that its independently developed HB0017 has successfully completed unblinding in a pivotal Phase 3 clinical study for moderate-to-severe plaque psoriasis, meeting all primary and key secondary endpoints. - At Week 12, 95.7% of patients in the HB0017 group…
Opens the 1L door for 397+trodelvy in mtap del UC
The FDA approval of EV + Pembro in cisplatin ineligible muscle invasive bladder is based on pCR=57% & OS HR of 0.5 vs cystectomy alone. Initial systemic therapy rather than surgery is now preferable for all eligible pts. I suspect this is not the last we hear from EVP in MIBC.
Correlation vs causation
May i meet you, hope you guess my name
Bill Ackman’s advice to young men has been mocked for being naive. It’s not a bad pickup line — but ultimately guys need to learn how to be interesting thetimes.com/us/news-today/…
Thanks
$IDYA is one of my top companies. I love their oncology pipeline. Its broad, its exciting and its potentially a big winner. My only concern is the valuation so I am waiting for the next bear market to build a bigger position.
United States 트렌드
- 1. Romero 19.3K posts
- 2. #twitchrecap 11.4K posts
- 3. Penn State 17.8K posts
- 4. #TADCFriend 1,216 posts
- 5. Slay 19.3K posts
- 6. Fulham 42K posts
- 7. #GivingTuesday 30.6K posts
- 8. Lewandowski 25.5K posts
- 9. Pat Kraft 1,847 posts
- 10. Larry 58.8K posts
- 11. Zion 8,992 posts
- 12. Pedri 47.1K posts
- 13. Adam Thielen 3,351 posts
- 14. Rashford 9,230 posts
- 15. Olmo 21.2K posts
- 16. Bentancur 2,612 posts
- 17. Paul Dano N/A
- 18. Newcastle 30.8K posts
- 19. Trump Accounts 26.4K posts
- 20. #AppleMusicReplay 11.9K posts
내가 좋아할 만한 콘텐츠
-
.
@CrocsAnalyst -
Erik A. Otto
@ErikOtto2 -
Biotech Jim
@JamesEKrause -
DRUGS
@drug_smolecules -
STL Biotech
@STL_Biotech -
Matthew Gamber
@MattBiotech -
Nick zheng
@pick1998_2 -
Keith Abrams
@DeepSouthDoctor -
Persimmon Tree Investments
@PersimmonTI -
FBCC
@BiotechPort -
pharmacreep
@pharmacreep -
German Biotech
@GermanBiotech -
Adam May
@A_May_MD -
WC
@Sanctuary_Bio -
avidresearch
@avidresearch
Something went wrong.
Something went wrong.